WD Rutherford LLC Has $338,000 Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

WD Rutherford LLC trimmed its position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 87.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,714 shares of the medical research company's stock after selling 11,914 shares during the quarter. WD Rutherford LLC's holdings in Charles River Laboratories International were worth $338,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in CRL. Tortoise Investment Management LLC grew its holdings in shares of Charles River Laboratories International by 77.0% during the 2nd quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company's stock valued at $27,000 after purchasing an additional 57 shares during the last quarter. Headlands Technologies LLC bought a new stake in shares of Charles River Laboratories International during the first quarter worth $41,000. Wolff Wiese Magana LLC acquired a new position in shares of Charles River Laboratories International during the third quarter worth $32,000. Whittier Trust Co. of Nevada Inc. lifted its stake in shares of Charles River Laboratories International by 219.3% in the 2nd quarter. Whittier Trust Co. of Nevada Inc. now owns 281 shares of the medical research company's stock valued at $58,000 after acquiring an additional 193 shares during the last quarter. Finally, Livforsakringsbolaget Skandia Omsesidigt acquired a new stake in shares of Charles River Laboratories International during the 3rd quarter valued at $79,000. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

CRL has been the subject of several research reports. Baird R W downgraded Charles River Laboratories International from a "strong-buy" rating to a "hold" rating in a research report on Thursday, August 8th. The Goldman Sachs Group cut their target price on shares of Charles River Laboratories International from $290.00 to $250.00 and set a "buy" rating on the stock in a research report on Thursday, August 8th. Redburn Atlantic assumed coverage on shares of Charles River Laboratories International in a research report on Monday, October 14th. They issued a "sell" rating and a $151.00 price target for the company. Bank of America lowered shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating and cut their price target for the stock from $250.00 to $215.00 in a report on Wednesday, October 2nd. Finally, Barclays decreased their price objective on Charles River Laboratories International from $230.00 to $210.00 and set an "equal weight" rating for the company in a report on Thursday, August 8th. Three equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $209.00.

Charles River Laboratories International Trading Down 1.4 %

CRL stock traded down $2.61 during mid-day trading on Wednesday, reaching $181.39. The company's stock had a trading volume of 792,289 shares, compared to its average volume of 602,513. The company has a market cap of $9.37 billion, a price-to-earnings ratio of 21.72, a price-to-earnings-growth ratio of 5.11 and a beta of 1.36. Charles River Laboratories International, Inc. has a 12 month low of $161.65 and a 12 month high of $275.00. The business's 50 day moving average price is $194.66 and its 200 day moving average price is $210.05. The company has a current ratio of 1.58, a quick ratio of 1.21 and a debt-to-equity ratio of 0.65.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its earnings results on Wednesday, August 7th. The medical research company reported $2.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.39 by $0.41. Charles River Laboratories International had a net margin of 10.83% and a return on equity of 14.96%. The company had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.03 billion. On average, equities research analysts predict that Charles River Laboratories International, Inc. will post 10.01 EPS for the current year.

Charles River Laboratories International announced that its board has approved a stock buyback plan on Wednesday, August 7th that permits the company to buyback $1.00 billion in shares. This buyback authorization permits the medical research company to buy up to 9.6% of its stock through open market purchases. Stock buyback plans are usually an indication that the company's leadership believes its stock is undervalued.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).